

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5715952

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATORY ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOSYS HOLDING CORPORATION LIMITED	09/10/2019
RECEIVING PARTY DATA	
Name:	REJUVEN DERMACEUTICAL CO LTD.
Street Address:	12F, DIC 3-A, 1193 JIANGNAN BOULEVARD
Internal Address:	BINJIANG DISTRICT
City:	HANGZHOU ZHEJIANG
State/Country:	CHINA
Postal Code:	310051
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12449541
CORRESPONDENCE DATA	
Fax Number:	(303)629-3450
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3036293400
Email:	docket.denver@dorsey.com
Correspondent Name:	DORSEY & WHITNEY LLP
Address Line 1:	1400 WEWATTA STREET
Address Line 2:	SUITE 400
Address Line 4:	DENVER, COLORADO 80202
ATTORNEY DOCKET NUMBER:	505282-00001
NAME OF SUBMITTER:	ANGELA M. STASCHKE
SIGNATURE:	/Angela M. Staschke/
DATE SIGNED:	09/12/2019
Total Attachments: 3	
source=Assignment_Biosys_Rejuven#page1.tif	
source=Assignment_Biosys_Rejuven#page2.tif	
source=Assignment_Biosys_Rejuven#page3.tif	

CONFIRMATORY ASSIGNMENT

This confirmatory Patent Assignment, having an effective date of 28 July 2016 ("Effective Date") is by and between Biosys Holding Corporation Limited, having its principal place of business at RMS 05-15 13A/F South Tower World Finance Center, Harbour City, 17 Canton Rd. TST, KLN, Hong Kong, China (the "Assignor") and Rejuven Dermaceutical Co Ltd., 12F, DIC 3-A, 1193 Jiangnan Boulevard Binjiang District Hangzhou Zhejiang China 310051 (the "Assignee");

WHEREAS, certain inventions are disclosed and described in US Patent Application No. 12/449,541(collectively, "the Patent Applications");

WHEREAS, Assignor has previously assigned to the Assignee all right title and interest in and to the Patent Applications under the terms of an Assignment dated 28 July 2016 and a confirmatory assignment dated 31 October 2017(having an effective date of 28 July 2016), and the parties desire to confirm both previous assignments; and

WHEREAS, to the extent that Assignor now owns any right, title and interest in and to the Patent Applications, Assignor desires to assign and Assignee desires to acquire any and all such rights, title and interest to the Patent Applications; any provisional, non-provisional, continuation, continuation-in-part, divisional, international, foreign, regional and convention applications corresponding thereto; any and all Letters Patent of the United States and countries and regions foreign thereto which may grant or have granted thereto or be lodged in relation thereto; any reissue or reexamination thereof or to be obtained therefor; any renewals or substitutes thereof; any and all priority rights or priority claims, or International Convention rights; any and all rights to collect past damages for infringement of any and all Letters Patent of the United States and countries and regions foreign thereto which may be published, which may grant, or have granted thereto or be lodged in relation thereto; and any other benefits accruing to or to accrue to Assignor with respect to the filing of applications for patents or securing of patents in the United States and countries foreign thereto (collectively, the "Patent Rights");


NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor confirms that it has sold, assigned, and transferred and by these presents does hereby sell, assign and transfer to the said Assignee, and said Assignee's successors and assigns, any and all of Assignor's entire right, title and interest in and to the Patent Rights; and

Assignor represents and warrants that Assignor has the right, title, and authority to execute this Assignment and to convey any and all right, title, and interest in the Patent Rights, and that Assignor has not conveyed nor will convey hereafter all or part of the Patent Rights to a third party. Assignor further represents and warrants that it will, upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings as may be necessary to perfect the Assignee's enjoyment of this grant, and execute acknowledgments of this assignment as necessary for full enjoyment of the Patent Rights and for recording in foreign patent offices. Assignor hereby authorizes said Assignee, its successors, and assigns, or anyone it may properly designate, to apply for Letters Patent in the U.S. and any and all foreign countries and regions, in its own name if desired, and additionally to claim priority to the filing date of the Patent Applications and otherwise take advantage of the provisions of any international conventions.

IN TESTIMONY WHEREOF, the Assignor, by its undersigned officer, confirms its assignment on the date and in the place set forth below.

Date: September 10, 2019

Biosys Holding Corporation Limited

By: 
Name: YONG GANG
Title: CEO


ACCEPTANCE OF ASSIGNMENT

The Assignee hereby acknowledges and accepts the foregoing assignment of rights by Assignor.

IN TESTIMONY WHEREOF, the Assignee, by its undersigned officer, confirms its acceptance on the date and in the place set forth below.

Date: September 10, 2019

Rejuven Dermaceutical Co Ltd.

By: 

Name: YANG GANG

Title: President & CEO